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avid R. Holmes, JR, MD, FACC,* Brian G. Firth, MD, PHD, FACC,† Douglas L. Wood, MD, FACC*
ochester, Minnesota; and Warren, New Jersey
Cardiovascular medicine is changing rapidly with the development, testing, and introduction
of new diagnostic and therapeutic methods. New interventional techniques such as the use of
drug-eluting stents have important implications for the care of individual patients and the
delivery and economics of health care in general. Drug-eluting stents have been shown to
improve outcomes among patients undergoing percutaneous coronary intervention by
significantly reducing restenosis rates. Two randomized trials have documented that per 100
patients treated with the sirolimus drug-eluting stent, 12.5 to 13.6 patients avoided the need
for subsequent target lesion revascularization, when compared with patients treated with
conventional stents. The economic effect of the introduction of these stents, which are
projected to be two to three times as expensive as conventional stents, is complex and depends
on which segment of health care is considered. These stents will be favorably received by
patients, physicians, employers, and society as well as payers. However, hospitals may be
adversely affected by having increased procedural costs for the stents, along with fewer
procedures for evaluation and treatment of restenosis and probably decreased surgical
volumes. Drug-eluting stents are only the first of many new technologic advances that will
affect cardiovascular care. These procedures have many features in common, including: 1)
replacement of major surgical procedures with less invasive approaches; and 2) redistribution
of costs, with a decrease in hospital profits but potentially lower costs of health care delivery
for society as a whole. (J Am Coll Cardiol 2004;43:507–12) © 2004 by the American
College of Cardiology Foundationo
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sealth care costs have attracted considerable attention from
he federal government, consumer organizations, the public,
nd health care professionals. In 2001, the estimated aver-
ge outlay for health care by every person in the U.S. was
5,035. Total outlays in hospitals were $451.2 billion, and
otal outlays for physicians and their services were $313.6
illion (1). A substantial percentage of this budget was spent
n cardiovascular diseases, the leading causes of morbidity
nd mortality throughout the Western world. Health care
osts for the treatment of cardiovascular diseases are com-
lex, involving patients, employers, third-party payers, the
ederal government, physicians, paramedical personnel, hos-
itals, and both device and pharmaceutical industries.
See page 513
Rapid changes within cardiovascular care are expected to
tress the various components of this complex system. These
hanges have resulted from the development, testing, and
ntroduction of new diagnostic and therapeutic methods
hat extend treatment opportunities for patients with estab-
ished disease and other treatment approaches before symp-
omatic disease develops. New interventional techniques
ave important implications not only for the care of indi-
idual patients but also for the delivery and economics of
ealth care in general.
From the *Division of Cardiovascular Diseases and Internal Medicine, Mayo
linic, Rochester, Minnesota; and the †Cordis Corporation, Warren, New Jersey.
Manuscript received March 7, 2003; revised manuscript received August 5, 2003,accepted August 25, 2003.This article explores the potential effect of new technol-
gy on the delivery of health care and defines the paradigm
hift, using the drug-eluting stent as an example. The
rug-eluting stent for the treatment of coronary artery
isease is probably only the first of several technologic
dvances that will redefine this paradigm.
URGICAL REVASCULARIZATION
oronary artery bypass graft surgery (CABG) is performed
requently; it is estimated that in 2001 there were approxi-
ately 520,000 of these operations in the U.S. (2). The
ndications for surgical revascularization vary. Surgical ther-
py, compared with medical therapy, has improved survival
n several subsets (e.g., in patients with two- or three-vessel
isease, particularly with left anterior descending coronary
rtery involvement or with abnormal left ventricular func-
ion) (3). Compared with conventional angioplasty, surgical
herapy has been found to improve survival in diabetic
atients (4–7). In the Bypass Angioplasty Revascularization
nvestigation (BARI) trial, at seven years after treatment,
6.4% of diabetic patients treated with CABG were alive,
ompared with 55.7% treated with angioplasty (4). The
xtent to which stents, particularly the drug-eluting stent,
ill mitigate this difference and improve survival remains to
e determined (8) and is scheduled to be tested in a
andomized multicenter clinical trial. In other groups,
urgical revascularization is performed to improve refractory
ngina or ischemia that cannot be controlled by either
m
(
r
i
a
(
i
b
b
a
p
e
d
i
o
C
i
p
I
P
a
s
q
l
t
m
t
b
g
e
g
a
t
O
p
g
i
t
i
d
a
t
t
1
o
r
p
d
i
w
a
s
e
c
n
i
q
d
r
f
s
R
w
t
t
n
y
g
T
s
t
g
d
o
s
O
t
w
H
a
t
f
o
T
R
C
S
D
508 Holmes Jr. et al. JACC Vol. 43, No. 4, 2004
Paradigm Shifts in Cardiovascular Medicine February 18, 2004:507–12edical therapy or percutaneous coronary intervention
PCI).
Surgical revascularization has often provided excellent
esults, although it has a number of limitations (Table 1),
ncluding costs associated with preoperative and postoper-
tive care, the need for several days of hospitalization
including intensive care), rehabilitation, and delayed or
nability to return to work. Because the useful life of venous
ypass grafts is seven to 10 years, some patients may need to
e re-treated, sometimes with results that are poorer than
fter the initial surgery. For the payer, the cost of these
rocedures is high—a minimum of $20,000 to $30,000 for
ach hospital stay. For the hospital, however, these proce-
ures constitute a substantial source of both revenue and net
ncome (9). In cardiovascular surgeons’ practices, CABG
ften provides the bulk of their income. Finally, for patients,
ABG is a major surgical procedure with attendant risks,
ncluding the well-recognized potential for neurologic com-
lications or a decline in neurocognitive function (10,11).
NTERVENTIONAL CARDIOLOGY
ercutaneous coronary intervention provides a less invasive
pproach for revascularization and offers a shorter hospital
tay and faster recovery. During the first decade of PCI, the
uality of results was limited by the lack of user-friendly and
esion-suitable technical equipment. Dissection and acute or
hreatened closure (12), resulting in major morbidity and
ortality, were sufficiently frequent and unpredictable so
hat in some institutions, an operating room was kept empty
ut staffed in case complications required emergency sur-
ery. An additional problem was restenosis. In one of the
arliest studies of percutaneous transluminal coronary an-
Abbreviations and Acronyms
ARTS  Arterial Revascularization Therapy Study
CABG  coronary artery bypass graft surgery
DRG  diagnosis-related group
FDA  Food and Drug Administration
ICD-9  International Classification of Diseases-
Ninth Revision
PCI  percutaneous coronary intervention
RAVEL  Randomized Study with the Sirolimus-
Eluting Bx VELOCITY Stent trial
SIRIUS  Sirolimus-Eluting Bx VELOCITY Stent trial
able 1. Advantages and Disadvantages of Surgical
evascularization Versus Percutaneous Coronary Intervention
Advantages Disadvantages
omplete revascularization Major operation
urvival advantage in selected subsets Longer duration for
ecreased need for second procedure hospitalization and recovery
Initial expense
Second procedure more difficult
Leg incisions
Limited life span of venous
bypass conduits (ioplasty, restenosis occurred in 33% of patients undergoing
ngioplasty from 1978 to 1980 (13).
In the largest multicenter trial of PCI with stenting—
he Prevention of REStenosis with Tranilast and its
utcomes (PRESTO), in which approximately 11,500
atients were enrolled from 1998 to 2000 —the angio-
raphic restenosis rate was also 33%, although this
ncluded more complicated types of lesions than those
hat are now being treated (14). Conventional stents
mprove the short-term outcome of PCI, mainly by
ecreasing the frequency of acute or threatened closure
nd obviating the need for urgent/emergent CABG. In
he most recent American College of Cardiology Na-
ional Cardiovascular Data Registry experience of
46,907 patients treated with PCI, surgery was required
r performed in 1.9% of the patients (15). In another
ecent series, from 1992 to 2000, emergency CABG was
erformed in only 0.61% (16). It has also been repeatedly
ocumented that angiographic restenosis rates with stent
mplantation are approximately 30% to 50% lower than
ith conventional percutaneous transluminal coronary
ngioplasty (17). Restenosis has not been eliminated by
tent implantation because, although stenting essentially
liminates acute recoil and late vessel remodeling (2
omponents of the restenotic process), it may aggravate
eointimal hyperplasia (18 –21).
In-stent restenosis may be recalcitrant. Treatment of
n-stent restenosis with conventional techniques still re-
uires subsequent intervention in 35% to 80% of patients,
epending on the specific lesion morphology. The effect of
estenosis on outcomes among patients who were candidates
or either PCI with stenting or CABG has been evaluated in
everal studies (22–24). In the largest such study—Arterial
evascularization Therapy Study (ARTS)—1,205 patients
ith multivessel disease were randomly assigned to be
reated with either conventional stenting or CABG. Al-
hough death, stroke, and myocardial infarction rates were
ot different between the two groups at one, two, and three
ears, the event-free survival at one year was significantly
reater with CABG (87.8%) than with stenting (73.8%).
his difference was related to restenosis and the need for
ubsequent procedures, which were required in only 3.8% of
he surgical group, as compared with 21.0% of the stent
roup. At three years, the only change was a slightly larger
ifference in the need for subsequent interventions. Because
f these additional procedures, the initial cost savings of
tent implantation relative to CABG decreased over time.
n the basis of these and other studies, some patients and
heir physicians may still choose CABG rather than PCI
ith stenting to avoid the need for subsequent procedures.
istorically at the Mayo Clinic, treatment of restenosis has
ccounted for 15% of the total number of yearly interven-
ional procedures. The need for several different procedures
or the treatment of coronary restenosis spawned the devel-
pment of new techniques such as vascular brachytherapy
25,26), which are effective but costly because they require
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February 18, 2004:507–12 Paradigm Shifts in Cardiovascular Medicinehe expertise of not only interventional cardiologists and
heir staff but also radiation oncologists and radiation
hysicists.
REATMENT WITH THE DRUG-ELUTING STENT
reatment of restenosis has complex economic implications:
) it is expensive for patients and payers; and 2) it is a source
f substantial revenue (and profit) for physicians and med-
cal care facilities, particularly fee-for-service institutions,
ecause of the return visits if restenosis is suspected or
resent and because of the subsequent angiography and
nterventions (either PCI alone, PCI with adjunctive vas-
ular brachytherapy, or CABG), which are highly profit-
ble. A new entrant—the drug-eluting stent—will dramat-
cally change the treatment of coronary artery disease in
erms of cost, quality, and value. At least two devices are
ell along in development and testing. For this discussion,
e highlight one—the sirolimus-eluting stent—which was
ecently approved by the U.S. Food and Drug Administra-
ion (FDA) on the basis of two randomized, double-
linded, controlled, multicenter clinical trials (27–30): 1)
he RAndomized Study With the Sirolimus-Eluting Bx
ELocity Stent (RAVEL) trial (Cordis Corp., Miami,
lorida), with 238 patients and a primary end point of
ngiographic restenosis at six months (late lumen loss); and
) the Sirolimus-Eluting Bx VELOCITY Stent (SIRIUS)
rial, with 1,100 patients and a primary end point of target
essel failure (cardiac death, myocardial infarction, or target
essel revascularization) at nine months.
The SIRIUS trial included somewhat higher risk patients
nd lesions (Table 2). There was a dramatic effect on
ngiographic restenosis both within the stent itself and
ithin the treated segment in each trial, and patients treated
ith a drug-eluting stent had a significantly decreased need
or subsequent intervention (Fig. 1) (27,30). Analysis of
arious clinical and angiographic subsets of the SIRIUS trial
ocumented a remarkably consistent and concordant im-
able 2. Characteristics of Patients in the SIRIUS and RAVEL
rials of the Sirolimus-Eluting Stent
Characteristics
SIRIUS
(n  1,058)
RAVEL
(n  238)
ale 71.2 75.6
ge (yrs) 62.3 60.6
revious MI 30.6 35.7
revious PCI 24.7 18.1
revious CABG 9.5 1.7
iabetes mellitus 26.4 18.5
yperlipidemia 73.6 51.5
ypertension 67.7 49.2
ultivessel disease 41.6 29.6
esion length (mm) 14.4 9.56
ontinuous data are presented as the mean value and categorical data as percentage
f patients.
CABG  coronary artery bypass graft surgery; MI  myocardial infarction; PCI
percutaneous coronary intervention; RAVEL  randomized study with the
irolimus-eluting Bx VELOCITY stent trial; SIRIUS  sirolimus-coated Bx VE-
OCITY stent trial.rovement in outcomes on the basis of angiographic and elinical end points with the drug-eluting stent. Per 100
atients treated with drug-eluting stents, 12.5 patients in
he SIRIUS trial and 13.6 patients in the RAVEL trial
voided subsequent target lesion revascularization.
Drug-eluting stents have important implications, not
nly for patients but also for the entire health care delivery
ystem. These implications were recognized by the U.S.
epartment of Health and Human Services and the Cen-
ers for Medicare and Medicaid Services in the final rule
ssued August 1, 2002, which created a new International
lassification of Diseases-Ninth Revision (ICD-9) code for
rug-eluting stents (code 36.07) and two new diagnosis-
elated groups (DRGs): drug-eluting stents with acute
yocardial infarction (DRG 526) and without acute myo-
ardial infarction (DRG 527). This step of creating a new
CD-9 code and new DRGs even before the use of a new
evice was approved by the FDA is unprecedented. It
ccurred for two reasons: 1) compelling clinical data; and 2)
vidence that these stents may be no more expensive at the
nd of one year, because the additional initial expense may
e offset by decreased subsequent interventions and the
otential shift from CABG to PCI. In addition, many
roups, including physicians and medical societies, sup-
orted the need for additional reimbursement to hospitals as
lose to the time of FDA approval as possible to blunt the
ffect of the increased cost of these devices.
Effective April 24, 2003, the use of the two new drug-
igure 1. (Bars on left) Rates of in-stent restenosis determined angio-
raphically in two clinical trials: 1) in the randomized study with the
irolimus-eluting Bx VELOCITY stent (RAVEL), the difference in
estenosis rates at six months between patients who had a sirolimus-eluting
tent and patients who had a control stent was 26.6% (p  0.001); and 2)
n the sirolimus-eluting Bx VELOCITY stent (SIRIUS) trial, the differ-
nce in restenosis rates at eight months between patients who had a
irolimus-eluting stent and patients who had a control stent was 32.2% (p
0.001). (Bars in middle) In-segment restenosis rates were higher than
n-stent restenosis rates (8.9% vs. 3.2%). This was related to arterial
arrowing adjacent to the stented segment. (Bars on right) Rates of
linically driven target lesion revascularization in two clinical trials: 1) in
AVEL, the difference in revascularization rates at 210 days between
atients who had a sirolimus-eluting stent and patients who had a control
tent was 13.6% (p  0.0001); and 2) in SIRIUS, the difference in
evascularization rates at 270 days between patients who had a sirolimus-
luting stent and patients who had a control stent was 12.5% (p  0.001).luting stent DRGs (nos. 526 and 527) will result in an
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Paradigm Shifts in Cardiovascular Medicine February 18, 2004:507–12dditional payment to hospitals by Medicare of approximately
2,100 as an average base increase over the national average
ase payments by Medicare in fiscal year 2002 (October 2,
001, to September 30, 2002) for bare-metal stents (DRGs
16 and 517). There is an additional adjustment to this
ifferential based on geographic location, indirect medical
xpense, and disproportionate care of indigent patients. The
esult is a national average increase of 22% to 24% (range 0%
o 50%), which varies by hospital. Thus, the average total
dditional reimbursement from Medicare is approximately
2,400 to $2,600. Because the base payment for bare-metal
tents (DRGs 516 and 517) increased from fiscal year 2002 to
scal year 2003 by approximately $300, the base additional
ayment for a drug-eluting stent within fiscal year 2003 is
pproximately $1,800 plus the applicable adjustment, as men-
ioned earlier (Fig. 2). The financial effect of drug-eluting
tents on each hospital depends on four variables: 1) additional
eimbursement per procedure by Medicare and other payers; 2)
dditional cost per stent; 3) number of stents used per proce-
ure; and 4) number of procedures performed, which may
hange if the threshold for intervention changes. The financial
mpact will depend on the mix of private pay, health mainte-
ance organization, and Medicare patients and the pricing of
tents.
One might assume that these stents would be used in all
ligible patients as soon as they are available. It is projected
hat the stents will be used in approximately 80% of eligible
atients by the fourth quarter of 2003. A fundamental
roblem is that drug-eluting stents are approximately three
imes more expensive than bare-metal stents. This will be a
articular problem if the number of stents used per patient
ncreases substantially.
HE PARADIGM SHIFT
n the U.S., the central elements of the paradigm shift in the
igure 2. National average base payments by Medicare for diagnosis-
elated groups (DRGs) 516 and 517 (bare-metal stents) and DRGs 526
nd 527 (drug-eluting stents) in fiscal year 2003. The base payment is $200
ore for DRG 516 and $450 more for DRG 517 than that in fiscal year
002. AMI  acute myocardial infarction.reatment of cardiovascular disease are related to patient, oayer, physician, hospital, and societal expectations of
ealth care financing.
atient expectations. Patients expect to have access to the
atest technology, although they may have little knowledge
f the cost or little willingness to pay for it. A new stent that
ppears to have no more adverse side effects than a conven-
ional stent, but which leads to markedly improved out-
omes with fewer subsequent revascularization procedures,
ill stimulate patient requests and increase expectations. In
his era of widespread distribution of medical knowledge to
he public and through the lay press and increased direct-
o-consumer advertising by industry, the pressures from
atients and families will most likely be intense. Attempts
y physicians or hospitals to limit the use of drug-eluting
tents on the basis of projected probabilities of restenosis
ay be received poorly by patients. Depending on the
eimbursement from the patient’s health care plan, a patient
ay be asked to pay more of the extra costs related to the
tent itself. Although FDA approval will most likely be for
he treatment of patients who have one lesion in one vessel
as in the randomized trials), drug-eluting stents will un-
oubtedly be used to treat multiple lesions in multiple
essels. Thus, the number of stents per patient may increase
ubstantially and exceed the average number of stents used
n patients, which is the number used in Medicare’s calcu-
ation of the average prospective payment to hospitals.
ayer expectations. There are several third-party payers
or cardiovascular care (Fig. 3). All of these groups are
oncerned with rising health care costs, and the up-front
igher initial costs of these new stents will be problematic.
owever, as is true for Medicare, these increased costs will
e at least partially offset by a substantially reduced need for
ubsequent procedures, even if the third parties pay more for
hese devices. In addition, the rates of CABG, traditionally
much more expensive procedure, will decrease as more
atients with multivessel disease, including left main coro-
ary artery disease and diabetes, are treated with drug-
luting stents.
The predicted cost savings related to a reduction in
estenosis rates may be rapidly offset by changes in practice,
n unknown factor. These changes will occur as more
atients are treated with stents instead of with medical
herapy alone. This trend is expected to occur with the
pread of knowledge about a safe therapy for the treatment
Figure 3. Third-party payers for cardiovascular procedures.f coronary stenosis with single-digit restenosis rates. As
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February 18, 2004:507–12 Paradigm Shifts in Cardiovascular Medicinendicated previously, on the basis of the SIRIUS and
AVEL trial data, an additional 125 to 136 patients per
,000 treated will avoid needing subsequent target lesion
evascularization within six to nine months when treated
ith a drug-eluting stent. This situation is highly favorable
or payers, and, even with the additional initial costs, it is
ikely to result in a cost-neutral or even cost-saving scenario.
hysician expectations. The challenge for cardiologists
ill be to determine how to implement drug-eluting stents
conomically and efficiently. For surgeons, the problem will
e substantially different because surgical volumes will
robably decrease as more data become available to support
he use of this therapy instead of CABG. Increasingly,
urgeons will be consulted only about patients in whom
hese stents cannot be placed; also, the overall outcomes of
urgery may worsen because of changes in case-mix as
ow-risk patients will receive interventional treatment and
nly high-risk patients will receive surgical treatment.
ospital expectations. Hospitals will face major changes.
he costs of PCI will increase because of the higher cost of
tents; this increase will probably surpass the increase in the
RG payment. The economic impact on hospitals with
espect to procedures performed on patients covered by
rivate payers will depend on the contractual arrangements
etween the hospital and private payers. At the same time,
ardiac surgery volumes will decrease, as will the number of
ercutaneous procedures performed to evaluate and treat
estenosis. The costs of surgical procedures will also increase
s sicker patients are treated, further eroding the margins of
rospective payments. These changes will create a signifi-
ant shortfall for many hospitals, particularly those with a
arge Medicare population.
ocietal expectations. From the societal standpoint, the
se of drug-eluting stents should offer substantial advan-
ages. Major surgical procedures will be replaced by less
nvasive procedures. Patients will need fewer hospitaliza-
ions and will have fewer recurrent symptoms. They may
eturn to work considerably sooner, with enhanced produc-
ivity, than if major surgery had been required. Cost
onsiderations are, however, complex: in the short term, this
herapy is likely to be cost-neutral or even cost-saving; in the
ong term, if survival is enhanced, additional spending
elated to noncoronary disease may increase.
eneral implications. Clearly, drug-eluting stents will be
eceived favorably by patients and physicians. However,
ospitals may be somewhat less enthusiastic because of the
otential for a negative effect on hospital budgets. The
dditional reimbursement from Medicare is an important
rst step to making this technology affordable. However,
ospitals receive approximately half of their reimbursement
rom private payers, who reimburse hospitals on the basis of
ndividual contracts that range from being advantageous for
ntroducing new techniques (e.g., percentages of charges
nd adjustments for use of new procedures) to disadvanta-
eous (e.g., per diem rates). Therefore, it behooves hospitals
o review and restructure these contracts, when possible, toaximize the hospital’s reimbursements for the use of new
echnologic advances. Hospitals will need to ensure that
hysician documentation is appropriate and that coding is
orrect.
ONCLUSIONS
he delivery of health care is increasingly complex. With
ew developments, paradigms of delivery must change.
rug-eluting stents are only the first of many new techno-
ogic advances that will affect cardiovascular care. Other
xamples of new cardiovascular device-based procedures
hat will affect the various constituencies differentially in-
lude carotid stenting with distal protection instead of
urgical carotid endarterectomy, abdominal aortic aneurysm
ndografts instead of open aneurysm repair, and intravas-
ular coil placement instead of open craniotomy for cere-
rovascular aneurysms. It is difficult to ignore the great
ppeal of procedures that entail local rather than general
nesthesia, less invasive approaches, shorter hospital stays,
nd more rapid return to work. These procedures have many
eatures in common: 1) They will replace major surgical
rocedures with less invasive approaches after documenta-
ion that these procedures are safe and yield either the same
r better outcomes than open surgical procedures. 2) Re-
istribution of costs will occur. Hospital profits are likely to
ecrease because the direct cost of the procedure will likely
ncrease, and it may not be adequately reimbursed, while
otal costs for society (comprising direct and indirect med-
cal and nonmedical costs, which include enhanced produc-
ivity due to more rapid return to work) may stay approxi-
ately the same or even decrease. 3) The use of new
reatments, which patients will request, will be good for
atients and society but may be problematic for hospitals
nd specific physician groups, especially surgeons, unless
hey become engaged in these new procedures.
The drug-eluting stent is only the most immediate and
bvious example of a major paradigm shift in the device-
ased treatment of cardiovascular disease. The successful
ncorporation of drug-eluting stents by a hospital may
herefore be a harbinger of how successfully a specific
nstitution may assimilate other new technologic develop-
ents and manage the changing treatment paradigm. This
xample also has important implications for health care
esourcing and for people who will provide the required
raining or credentialing of physicians, nurses, technicians,
nd other caregivers.
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ivision of Cardiovascular Diseases and Internal Medicine, Mayo
linic, 200 First Street SW, Rochester, Minnesota 55905. E-mail:
olmes.david@mayo.edu.
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